PressJuly 17, 2024 Psyched Wellness Adds Harmons to List of Retail Partners, Engages UNFI For Distribution, and Announces Appointment of Kyle Nazareth as Chief Financial Officer
PressJuly 16, 2024 Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial
PressJuly 16, 2024 Braxia Scientific Announces Application for a Management Cease Trade Order For Late Filing of Audited Annual Financial Statements
PressJuly 16, 2024 Algernon Pharmaceuticals Reports Results of Study Showing 93% Cough Suppression with Ifenprodil
PressJuly 16, 2024 Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
PressJuly 16, 2024 SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
PressJuly 12, 2024 Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
PressJuly 10, 2024 Cybin Inc. Stands Strong As A Remaining Force To Prove Benefits Of Psychedelic Therapeutics ($CYBN)
PressJuly 9, 2024 Red Light Holland CTIO to Unveil Groundbreaking iMicroapp Research Findings to Prestigious Drug Science Consortium
PressJuly 8, 2024 Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders
PressJuly 8, 2024 Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
PressJuly 8, 2024 Clearmind Medicine Inc. Announces Advancement in its Proprietary MEAI- Based Binge Behaviors Treatment
PressJuly 3, 2024 Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
PressJuly 1, 2024 Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
PressJune 27, 2024 MindBio Therapeutics Corp. Reports Durability Data from Phase 2A Clinical Trials in Depressed Patients Testing MB22001
PressJune 27, 2024 Optimi Health and Mind Medicine Australia Launch OptiMed Prescriber Portal for Australian Psychiatrists
